The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 57 results
July 2026
-
Media Release
Novartis receives Health Canada approval for ᴾʳRHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU
RHAPSIDO® (remibrutinib tablets) is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. 1The phase III… -
Media Release
Novartis receives Health Canada approval for VANRAFIAᵀᴹ (atrasentan tablet) for proteinuria reduction in adults with primary immunoglobulin A nephropathy (IgAN)
VANRAFIATM (atrasentan tablets) is indicated to reduce proteinuria in adults with IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.1In the…
June 2026
-
Media Release
Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser
The MS Tri-Challenge returns to Montreal on Saturday, September 12, 2026, at Parc Jean-Drapeau as part of the Sail Challenge Esprit de MontréalSince 2010, Novartis Canada has raised over $… -
Media Release
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets)
MONTREAL, June 3, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance…
May 2026
-
Media Release
Novartis Canada Recognizes Next Generation of Oncology Innovators Through NOYCIA Awards at ASCO
MONTREAL, May 26, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to unveil the recipients of the 2026 Novartis Oncology Young Canadian Investigator Awards (NOYCIA),… -
Media Release
Novartis Canada launches third edition of its Health Equity Initiative, prioritizing Women’s Health
Montreal, May 14, 2026 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) today announces the third edition of its Health Equity Initiative, reaffirming its… -
Media Release
Novartis Canada Recognizes MS Awareness Month with the Third Annual My Krew Campaign
Approximately 90,000 Canadians live with multiple sclerosis (MS), a disease that impacts the central nervous system.1 Canada has one of the highest rates of MS in the world, with an average of 12… -
Media Release
Novartis receives Health Canada approval for ᴾͬ Fabhalta® oral treatment for adults with C3G
Fabhalta® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria.1Phase III APPEAR-C3G…
December 2025
-
Media Release
Scemblix® Receives Positive Funding Recommendations from INESSS for Newly Diagnosed and Previously Treated Adult Patients with Chronic Myeloid Leukemia
Novartis Canada applauds the positive funding recommendations for Scemblix® (asciminib) for both newly diagnosed and previously treated patients with Philadelphia chromosome-positive chronic myeloid… -
Media Release
Scemblix® Receives Priority Access in Ontario Under New FAST Program
Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix® for patients living with cancer.Scemblix® (asciminib) was…